New AI Partnership to Transform Pathology in India
Qritive platform/Photo from Qritive
Singapore-headquartered Qritive, a leading provider of AI solutions for pathology labs worldwide, has partnered with three diagnostic centers and hospitals in India: Metropolis Healthcare, a leading diagnostics company in India; Rajiv Gandhi Cancer Institute (RGCI), a non-profit medical facility and research institute based in Delhi; and CŌRE Diagnostics, a leading name in high-end and specialized diagnostics in India. These institutions have embraced the Pantheon image management system (IMS) and Qritive’s AI products, leading in the adoption of artificial intelligence in pathology workflows. By leveraging the power of artificial intelligence, these institutions are enhancing diagnostic accuracy, improving operational efficiency, and ultimately advancing patient care.
Related: Singapore Advances Healthcare, Tackle Issues with Technology and AI
Surendran Chemmenkottil, CEO of Metropolis Healthcare, expressed his company’s enthusiasm for the partnership, stating that the integration of Qritive’s AI-powered platform into their workflows signifies a revolutionary step in enhancing precision, timeliness, and personalized diagnosis. This collaboration reinforces Metropolis Healthcare’s commitment to setting a new standard in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection.
Bruno Occhipinti, CEO of Qritive, meanwhile, stated that their whole team is eager to showcase how deep tech will support clinicians and contribute to “closing the gap” in cancer care.
Dinesh Chauhan, CEO of CŌRE Diagnostics, also hailed the partnership, pointing to the potentials of integrating advanced AI solutions into CŌRE Diagnostics’s pathology workflow. This collaboration is expected to strengthen its diagnostic precision, resulting in improved patient outcomes. The collaboration also has the potential to lead to the development of new AI services for the diagnosis of rare diseases, he said.
The implementation of Qritive’s AI-powered platform significantly transforms pathology workflows. Clinical studies carried out at prominent healthcare institutions reveal up to a 90% reduction in the time needed for diagnoses and up to an 80% decrease in discordance among pathologists. Such improvements lead to increased diagnostic accuracy and an overall enhancement in the quality of care for cancer patients.
Gurudutt Gupta, HOD Pathology at the RGCI Research Centre, said that Qritive’s IMS and AI modules have enhanced pathology practice at RGCI. With efficient identification of concerning areas and precise grading, integrating these tools has enhanced their workflow and diagnostic precision, offering significant benefits to its practice.
Category: Technology & Devices
